Dissociative Drug Use Disorders: Ketamine and PCP
Author: Angela Bogdanova · Published: October 19, 2026 · Editorial Policy
Research cluster: Substance Use Disorders and Addiction Recovery · Written by Artificial Sapiens
Dissociative drugs such as ketamine and phencyclidine (PCP) can produce transient changes in awareness, perception, body sensation, memory, pain perception, and the experience of self. Repeated nonmedical use may become compulsive and develop into a clinically significant substance use disorder. The clinical picture also includes immediate intoxication hazards and, particularly with frequent ketamine exposure, potentially serious injury to the urinary tract. Understanding these conditions requires distinguishing a persistent disorder of substance use from an episode of intoxication, an isolated adverse effect, prescribed medical treatment, and another mental or medical condition. The World Health Organization's ICD-11 clinical framework explicitly recognizes disorders due to dissociative drugs, while contemporary systematic reviews of ketamine misuse treatment emphasize how limited the treatment-specific trial evidence remains.
What Are Dissociative Drug Use Disorders?
A dissociative drug use disorder is a persistent or recurring pattern of using a dissociative psychoactive substance that produces clinically important impairment, harmful consequences, or impaired control and meets the applicable diagnostic requirements. Ketamine and PCP are the principal examples addressed here. Both alter glutamatergic signaling, especially through antagonism of the N-methyl-D-aspartate (NMDA) receptor, but they differ in their patterns of exposure, medical applications, pharmacology, and prominent harms. People can experience significant intoxication after a single exposure without having a use disorder; conversely, someone with an established use disorder may seek help when no longer intoxicated.
The term ketamine use disorder is widely used in research and clinical discussion to describe a problematic pattern of ketamine consumption. Its precise coding depends on the diagnostic system and jurisdiction. The DSM-5-TR groups ketamine with phencyclidine or pharmacologically similar substances, whereas ICD-11 expressly identifies disorders due to dissociative drugs including ketamine and PCP. These classifications address a clinically coherent problem, although their individual diagnostic categories and thresholds should be applied on their own terms. The WHO diagnostic requirements provide an international reference.
Substance use, hazardous use, and clinical disorder
Substance use describes exposure, not a diagnosis. Hazardous or risky use describes a pattern associated with increased likelihood of harm. Misuse is a context-dependent term that may refer to nonmedical use, use contrary to prescription, or use in ways that produce harm, and does not by itself establish addiction. A disorder is established through assessment of symptoms, consequences, control over use, duration, and the recognized diagnostic framework. A patient who develops bladder pain after intermittent ketamine use may have an important drug-related medical condition even if the threshold for a substance use disorder is not met. Another patient may fulfill use-disorder criteria through intense craving, repeated unsuccessful efforts to stop, and abandonment of activities even before obvious physical complications become apparent.
Addiction, dependence, tolerance, and withdrawal
Addiction is a clinical and scientific term commonly used for severe or compulsive substance use associated with impaired control and continued consumption despite consequences. Physical dependence describes physiological adaptation to exposure; tolerance describes a diminished response to the same exposure or need for greater exposure to obtain a comparable effect. Neither proves compulsive use. Withdrawal refers to symptoms arising when exposure is reduced or stopped after adaptation. In ketamine use, craving, dysphoria, anxiety, sleep disruption, and other complaints have been described during cessation, yet a distinct, reproducible physiological withdrawal syndrome is considerably less well established than alcohol or benzodiazepine withdrawal. In its description of dissociative drug disorders, ICD-11 does not treat a conventional withdrawal syndrome as a consistently recognized defining feature. This uncertainty matters when clinicians assess symptoms rather than inferring a medically dangerous withdrawal syndrome from the word dependence.
Ketamine and PCP: Pharmacology and Clinical Differences
Ketamine is a dissociative anesthetic with established medical applications in anesthesia and procedural sedation. Specific ketamine- or esketamine-based interventions also exist in tightly controlled psychiatric settings, with distinct regulatory and safety requirements. PCP is a dissociative substance with a different clinical history and no comparable routine contemporary human therapeutic role. The public-health problem addressed in this article concerns nonmedical exposure and its consequences. Prescribed ketamine administration, misuse of prescribed supplies, and illicit ketamine consumption require different histories and safety evaluations, even though the active molecule may be the same.
NMDA receptor antagonism and altered perception
Both substances reduce signaling through NMDA-type glutamate receptors, affecting networks involved in perception, sensory integration, memory, movement, cognition, and coordination. Their effects can involve a sense of detachment from body or surroundings, altered timing and distance, disrupted memory formation, and diminished responses to painful stimuli. The resulting state is described as dissociation. It can coexist with euphoria, anxiety, confusion, or psychotic symptoms depending on the exposure, individual vulnerability, setting, and other substances present. NMDA antagonism offers a biologically grounded explanation of many acute effects, but no single receptor mechanism adequately explains the emergence of an enduring substance use disorder in every person.
Ketamine: distinctive exposure and harm profile
Nonmedical ketamine is encountered in nightlife and other recreational environments, but patterns extend beyond any one population or social setting. Some people use it intermittently; others progress to frequent or prolonged consumption, develop strong cue-associated urges, or use it to manage distress. Repeated exposure can be associated with memory and attention problems, abdominal or upper urinary tract symptoms, and especially ketamine-associated cystitis and uropathy. These physical symptoms deserve direct attention even when patients initially request help primarily for mental health or substance-use concerns. A 2024 British Association of Urological Surgeons consensus sets out assessment and management principles for ketamine-related urinary problems.
PCP: distinctive acute toxicology
PCP intoxication can include marked agitation, fluctuating alertness, impaired coordination, unusual eye movements including nystagmus, hypertension, muscle rigidity, disorganized behavior, paranoia, and hallucinations. Severe toxicity can progress to hyperthermia, seizures, traumatic injury, rhabdomyolysis, or coma. Some manifestations resemble intoxication by stimulants or other agents; others resemble primary psychosis or delirium. A clinical assessment therefore emphasizes vital signs, the possibility of co-ingestion, neurological status, and exclusion of urgent alternative diagnoses. The NCBI clinical toxicology review documents this heterogeneous presentation and the need for monitored emergency care when severe symptoms occur.
How Problematic Ketamine or PCP Use Develops
A substance use disorder develops through interacting learning, biological, psychological, interpersonal, and environmental processes. The experience of a dissociative state may initially be sought for novelty, social participation, mood alteration, sensory effects, or perceived relief from emotional distress. With repetition, contexts associated with use can become learned cues. Expectations of relief or reward, access to the substance, and changing habits may make future use more likely. Risk develops along a continuum and depends on the person and their circumstances rather than following an inevitable sequence.
Reward, learning, and craving
Glutamatergic disruption interacts with broader circuitry governing reward prediction, reinforcement, memory, and behavioral control. People may learn that dissociation temporarily reduces distressing experiences, and this negative reinforcement can support repeated use even when the overall consequences become increasingly unfavorable. Craving may be triggered by social contacts, specific environments, emotional states, or drug-related cues. These are explanatory mechanisms consistent with addiction science, but their relative contributions to ketamine or PCP disorders have not been quantified with the precision available for some more extensively studied substances.
Tolerance, escalating frequency, and functional change
Tolerance may develop during repeated nonmedical ketamine exposure, and some patients describe increasing amounts or frequency as desired effects become less salient. Clinical concern grows when obtaining, using, or recovering from the drug consumes time; study, employment, and relationships deteriorate; or use continues despite clear pain, psychological changes, financial consequences, or repeated efforts to stop. A history of escalation is clinically informative but is not required in every case. Self-reported quantities are often imprecise, and illicit substance composition may be uncertain. Functional change over time can be more reliable for assessment than a single numerical estimate of consumption.
Psychiatric vulnerability and self-medication
Anxiety, depression, trauma-related symptoms, sleep problems, social pressure, and other mental health difficulties may be associated with nonmedical dissociative drug use. Their relationship may operate in both directions: distress can precede use, while intoxication, disrupted sleep, medical complications, and the consequences of compulsive use can aggravate distress. Observational associations alone do not establish that a specific psychiatric condition caused the disorder. A careful clinical formulation asks what symptoms preceded substance exposure, what changes during periods without use, and which problems need treatment in parallel. The distinct broader topic of co-occurring psychosis is examined in Substance-Induced Psychosis: Causes, Symptoms, and Treatment.
Diagnostic Classification: DSM-5-TR and ICD-11
Diagnostic classification provides a shared language for clinical decisions and epidemiologic research. It does not replace a history, examination, or contextual judgment. Because ketamine research often uses terms such as ketamine dependence or ketamine use disorder outside a uniform clinical assessment, clinicians should ask exactly how investigators defined their study participants before comparing reported prevalence or treatment results.
DSM-5-TR: a phencyclidine-related substance use disorder
The DSM-5-TR framework for phencyclidine use disorder also covers pharmacologically similar substances such as ketamine. Core substance-use criteria include using more than intended, persistent unsuccessful attempts to reduce use, considerable time spent obtaining or recovering from the substance, craving, impaired obligations, interpersonal conflict, reduced activities, hazardous use, and continued use despite recognized harm. Tolerance may contribute where appropriate. The severity framework counts applicable criteria over approximately 12 months: two or three indicates mild disorder, four or five moderate disorder, and six or more severe disorder. Applying criteria requires attention to their substance-specific exclusions; a clinically established physiological withdrawal criterion should not simply be presumed for PCP or ketamine. A clinician also differentiates expected medication effects under appropriate medical supervision from problematic use.
ICD-11: disorders due to dissociative drugs
ICD-11 uses a substance-specific grouping for dissociative drugs including ketamine and PCP, coded within 6C4D. The framework distinguishes harmful episodes or patterns of use, dependence, intoxication, delirium, and substance-induced mental disorders. Dependence involves impaired regulation of use, increasing priority assigned to use, and physiological or behavioral features interpreted in clinical context. The WHO explicitly recognizes dissociative drug dependence while acknowledging the unsettled status of a characteristic withdrawal syndrome. DSM and ICD categories should not be treated as numerically interchangeable. For clinical coding, the relevant national implementation and current WHO ICD-11 requirements govern.
Diagnosis requires an interview, not a screening score
Screening identifies a possible need for further assessment. A comprehensive clinical assessment evaluates patterns of use, associated symptoms, medical and mental health history, safety risks, and functioning. Diagnosis requires evidence that the applicable criteria have been met and that another condition does not better account for the presentation. No laboratory test, drug-screen result, frequency threshold, or single bladder symptom diagnoses ketamine use disorder. In practice, a patient may need several complementary diagnoses: for example, a substance use disorder and ketamine-associated bladder injury, or an acute intoxication syndrome and a separately established psychiatric illness.
Symptoms and Warning Signs of Persistent Dissociative Drug Use
Clinical presentations range from concealed but increasingly disruptive use to repeated emergency visits, severe pain, cognitive complaints, or marked psychiatric symptoms. Some individuals seek help for physical symptoms and only later disclose repeated ketamine exposure. A respectful, specific substance history improves the opportunity to connect apparently unrelated symptoms without assigning an unsupported diagnosis.
Behavioral and functional symptoms
Signs may include persistent desire to use, intense preoccupation with access, craving after intentions to stop, difficulty controlling frequency, missed responsibilities, withdrawal from relationships or valued activities, and continued use despite adverse consequences. Financial strain, risky situations while intoxicated, or reduced ability to maintain work and daily routines can accompany the disorder. The clinical meaning comes from a sustained pattern and impairment, not from moral judgments about substance use.
Cognitive, emotional, and perceptual symptoms
Memory lapses, concentration problems, impaired executive function, mood instability, anxiety, low motivation, and dissociative or psychotic-like experiences have been reported among people with repeated ketamine exposure. The systematic review of long-term ketamine-associated brain changes found differences in structural and functional measures across observational samples, but these results do not prove that every change was caused by ketamine or that all changes persist after cessation. Potential confounding includes sleep, psychiatric comorbidity, exposure duration, and other substance use. Cognitive complaints should prompt both substance-use assessment and consideration of other medical and psychiatric explanations.
Physical symptoms deserve equal attention
Frequent urinary urgency, repeated small-volume urination, painful urination, pelvic or bladder pain, visible blood in urine, flank discomfort, and recurrent urinary symptoms can suggest ketamine-associated uropathy. Abdominal pain and nausea may accompany chronic exposure, although they have multiple possible causes. An individual may underestimate the relevance of repeated ketamine exposure because the first concern appears to be a bladder or gastrointestinal problem. Early clinical evaluation is especially important when symptoms are progressive, associated with blood in urine, or impairing daily functioning. Urological consensus guidance supports integrated assessment rather than treating symptoms in isolation.
Ketamine-Associated Bladder and Urinary Tract Injury
Ketamine-associated uropathy is one of the most distinctive and potentially disabling consequences of sustained nonmedical ketamine exposure. The presentation ranges from bothersome lower urinary tract symptoms to ulcerative bladder injury, reduced functional bladder capacity, upper urinary tract obstruction, and kidney involvement. Severity varies considerably. Some people improve after stopping ketamine, while others need specialist treatment and may have enduring symptoms or tissue damage. The British Association of Urological Surgeons consensus gives the condition a dedicated management pathway.
Lower urinary tract symptoms and ketamine-associated cystitis
Affected individuals may experience urinary frequency, urgency, nocturia, bladder or suprapubic pain, painful urination, or hematuria. Symptoms can interfere with sleep, employment, travel, relationships, and social participation. The combination of ongoing exposure, chronic pain, and functional disruption may further complicate attempts to reduce use. Clinicians should assess urinary infection, stones, inflammatory bladder disorders, malignancy when indicated, and other explanations rather than assuming every symptom is ketamine-related. Exposure history and appropriate medical investigations guide the differential diagnosis.
Upper urinary tract and renal complications
In more advanced cases, inflammation, scarring, reduced bladder capacity, and urinary tract obstruction can affect the kidneys. Flank pain, impaired renal function, or imaging evidence of obstruction warrants prompt specialist evaluation. Severe presentations may require urgent urological procedures and multidisciplinary follow-up. The extent of kidney or bladder injury cannot be inferred from subjective pain alone; some patients need urine testing, renal-function measurements, imaging, and specialist investigations selected according to the findings. Visible blood in urine, fever with urinary symptoms, inability to pass urine, or severe flank pain merits urgent medical attention.
Can the bladder recover after stopping ketamine?
Stopping ketamine exposure is a central component of management and gives symptoms the best opportunity to improve. Recovery depends on how advanced the injury is and whether structural complications have developed. Some patients report substantial improvement; others continue to experience pain or functional limitation after abstinence and need targeted urological care. Claims of guaranteed reversal or a fixed recovery timeline exceed the evidence. Specialist teams may address pain, urinary function, obstruction, and psychological barriers to maintaining cessation concurrently. This is an example of why treatment for the use disorder and treatment for its medical consequences must proceed together.
Acute Ketamine Intoxication and Emergency Risks
An acute ketamine episode may involve dizziness, impaired coordination, confusion, disorientation, distorted perception, dissociation, altered awareness of danger, vomiting, or sedation. The person may become unable to protect themselves from falls, drowning, traffic incidents, or other injuries. Co-use with alcohol, opioids, benzodiazepines, and other sedating substances raises additional concern about impaired consciousness and breathing. Street products of uncertain composition introduce further diagnostic uncertainty. Emergency clinicians assess the observed syndrome and physiological status rather than relying solely on the reported substance name.
Severe sedation and respiratory concerns
Ketamine's effects on respiration during monitored medical anesthesia differ from the unpredictable risks of nonmedical exposure, especially with multiple substances. A person who is difficult to awaken, breathes abnormally, has bluish lips, repeatedly vomits while barely conscious, or has a seizure requires emergency services immediately. Bystanders should obtain emergency help and follow dispatcher instructions, including basic life support when directed. If opioid exposure is possible, emergency responders may administer naloxone, but naloxone is an opioid antidote and does not reverse ketamine or PCP effects themselves.
Agitation, confusion, and injury
Some people become frightened, agitated, or disorganized during intoxication, and perceptions of surroundings may be unreliable. The safest response prioritizes professional assessment, injury prevention, and a calm environment rather than confrontation. Intoxication can obscure head trauma, hypoglycemia, infection, and other emergencies. Persistent confusion, new neurological deficits, or a dangerous change in behavior requires urgent evaluation even if drug use has been reported.
PCP Intoxication, Delirium, and Medical Emergencies
PCP has a clinically distinctive profile of dissociation combined in some cases with marked sympathetic activation and severe behavioral or neurological disturbance. Intoxication may fluctuate, making a single observation insufficient for risk assessment. The clinical toxicology literature identifies cardiovascular, neurological, metabolic, psychiatric, and traumatic complications that warrant emergency attention.
Common clinical findings
A clinician may observe nystagmus, impaired judgment, ataxia, slurred speech, hypertension, rapid heart rate, reduced response to pain, agitation, hallucinations, or alternation between excitement and reduced responsiveness. The appearance is variable, and specific signs are neither universal nor individually diagnostic. Severe disturbance may resemble delirium or a primary psychiatric episode, so assessment of medical causes and other drugs remains essential.
Hyperthermia, seizures, rhabdomyolysis, and coma
Marked agitation and muscle activity can contribute to high body temperature, muscle injury, and metabolic complications. Seizures, serious hypertension, abnormal breathing, unconsciousness, and traumatic injuries are critical warning signs. Rhabdomyolysis can impair kidney function and may be suspected when severe agitation, muscle injury, or abnormal laboratory tests are present. These are hospital-level concerns. Medical teams monitor airway and circulation, temperature, neurological status, and associated complications; appropriate medications and supportive interventions are selected by trained clinicians. A home-management protocol is not a substitute for emergency care.
Emergency psychiatric symptoms and safety
PCP intoxication can involve intense fear, paranoia, hallucinations, aggressive behavior, or self-endangering actions. The behavior may arise from an altered state of consciousness rather than an enduring psychiatric diagnosis. Safety assessment includes risk of accidental injury, violence, and self-harm, while providing respectful care and minimizing unnecessary stimulation. A person with dangerous agitation, inability to maintain safety, or suicidal behavior needs emergency medical and psychiatric assessment. Any psychiatric diagnosis made after an intoxication episode should be reviewed once the acute physiological effects have resolved.
Ketamine, PCP, and Substance-Induced Psychosis
Dissociative drug exposure can cause psychotic-like experiences, including paranoia, hallucinations, and disruptions of reality testing. Some occur during intoxication and diminish as the substance is cleared; others persist and require evaluation for a substance-induced psychotic disorder or an independent psychotic illness. A clinical history examines temporal relationships, persistence after intoxication, previous psychotic episodes, family history, mood symptoms, sleep loss, and co-ingested substances. This article addresses dissociative-drug-specific risk; the broader diagnostic framework belongs to Substance-Induced Psychosis.
Distinguishing transient experiences from a disorder
An unusual perceptual experience during exposure is not itself sufficient for a schizophrenia-spectrum diagnosis. Similarly, a psychotic episode following ketamine or PCP use does not automatically establish that the substance caused every symptom. When psychosis is persistent, recurrent outside intoxication, or accompanied by major functional decline, clinicians assess primary psychiatric conditions and medical causes. Emergency medical care is appropriate for severe disorganization, unsafe behavior, or inability to care for basic needs. Follow-up after acute stabilization is important because diagnostic understanding may change with longitudinal observation.
What Does Ketamine or PCP Withdrawal Look Like?
People stopping frequent nonmedical ketamine use sometimes describe strong craving, anxiety, dysphoria, irritability, difficulty sleeping, tiredness, and changes in appetite or mood. These experiences can be distressing and associated with recurrence of use. However, published evidence has not established a uniform, predictable physiological withdrawal syndrome comparable with alcohol or benzodiazepine withdrawal. Reports often come from clinical samples with co-occurring mental health conditions or other drug exposure. The systematic review of treatment approaches illustrates the limited evidence base for pharmacological symptom management.
Clinical evaluation during cessation
Assessment asks about exposure frequency, other substances, sleep, mood, craving, suicidal thoughts, medication use, prior severe reactions, and available support. The clinician also evaluates physical conditions such as ketamine-associated urinary injury and whether treatment for another substance may carry dangerous withdrawal risks. Severe agitation, new psychosis, seizures, suicidal intent, major confusion, or signs of serious medical illness require urgent professional care, irrespective of whether a withdrawal label is applied. Alcohol and benzodiazepine withdrawal in a person who also uses ketamine must be assessed on their own potentially life-threatening terms.
Why a generalized detoxification protocol is inappropriate
There is no universally established medication protocol for ketamine or PCP withdrawal. A clinically supervised plan may involve monitoring, supportive care, treatment of coexisting conditions, and individualized symptom assessment. Medications reported in case studies are not equivalent to validated treatment regimens, and unsupervised use of sedatives or other drugs may create further harm. Detoxification, even when useful for acute stabilization, does not by itself address craving, learned routines, psychiatric needs, urinary injury, or the social circumstances affecting recurrence.
Screening and Comprehensive Clinical Assessment
A high-quality assessment begins with a collaborative, nonjudgmental conversation about what is being used, why, under what circumstances, and with which consequences. Clinicians ask about prescribed and nonprescribed substances, frequency and recent changes, co-use, prior attempts to stop, tolerance, craving, injuries, memory complaints, urinary symptoms, mental health history, sexual health where relevant, and how functioning has changed. Patients should feel able to disclose uncertain substance identities without fear of being reduced to a label.
Substance history and temporal pattern
Clarifying whether symptoms occur during intoxication, afterward, or during sustained periods without the substance is central to differential diagnosis. Assessment also explores whether a medically prescribed ketamine treatment exists, whether the patient used additional nonprescribed ketamine, and whether products of unknown composition were obtained elsewhere. The same symptom can indicate different conditions depending on timing: dissociation during exposure, panic after exposure, persistent psychosis, urinary pain unrelated to use, or another medical disorder each requires a distinct evaluation.
Screening instruments and their limitations
General substance-use screening questionnaires can help identify a possible clinical problem, but most were not designed to establish a ketamine-specific or PCP-specific diagnosis. A positive result should prompt an interview, while a negative result does not override credible evidence of significant complications or impaired control. Screening tools cannot reliably determine the severity of ketamine uropathy, distinguish drug-induced psychosis from primary psychosis, or certify that intoxication is medically safe. Their role is preliminary identification and triage.
Physical examination and targeted investigations
Investigations are selected according to clinical findings, not ordered indiscriminately. During severe acute intoxication, clinicians may assess vital signs, consciousness, glucose, electrolytes, kidney function, electrocardiographic findings, muscle injury markers, and evidence of trauma. With urinary complaints, urinalysis, evaluation for infection, renal function, ultrasound, and urological referral may be indicated. Persistent cognitive or psychiatric complaints deserve formal assessment. Laboratory testing may help identify complications, but the diagnosis of substance use disorder remains clinical.
What a urine drug screen can and cannot tell us
Standard toxicology panels vary considerably. Many do not routinely include ketamine, and PCP immunoassays may produce false-positive results or remain positive after acute impairment has passed. A negative result cannot definitively exclude exposure, while a positive result cannot establish when use occurred, current intoxication severity, or a substance use disorder. Confirmatory testing may be required when the result has major clinical or legal consequences. The PCP clinical toxicology reference discusses both persistence and cross-reactivity of screening results.
Differential Diagnosis and Co-Occurring Conditions
A substance-related explanation should be considered alongside other plausible causes. Acute confusion may arise from alcohol or sedative intoxication, stimulant toxicity, metabolic disturbances, infection, head injury, epilepsy, or psychiatric illness. Persistent dissociation may occur in trauma-related conditions without a dissociative drug use disorder. Memory complaints can arise from sleep loss, depression, medication effects, nutritional problems, or neurological disease. Urinary frequency and pain require evaluation for infection, stones, inflammatory or structural urinary tract disease, and other relevant diagnoses.
Psychological dissociation versus drug-induced dissociation
Dissociation is a descriptive experience that can occur in different conditions and contexts. Dissociative identity disorder, depersonalization/derealization disorder, trauma-related dissociation, and transient drug-induced dissociation do not share one diagnostic explanation. History of substance exposure and the symptom timeline are critical. The canonical clinical diagnosis of dissociative disorders is addressed separately in Dissociative Disorders: Types, Symptoms, Diagnosis, and Treatment, preserving its distinct diagnostic intent.
Co-occurring psychiatric and substance use conditions
Depression, anxiety disorders, trauma-related problems, psychosis, and other substance use disorders can affect treatment planning. The clinician determines which symptoms can be safely assessed immediately and which need reassessment after acute intoxication resolves. Integrated care may include addiction professionals, primary care, psychiatry, and urology. A dual-diagnosis formulation is an opportunity to coordinate treatment rather than to presume that all symptoms have a single origin. SAMHSA guidance on co-occurring disorders supports coordinated approaches.
Evidence-Based Treatment: What Is Established and What Remains Uncertain?
Treatment should address the pattern of compulsive use, associated psychiatric problems, physical complications, and the patient's goals. Evidence for dedicated ketamine and PCP interventions remains much thinner than evidence for many other substance use disorders. A scientific treatment plan therefore distinguishes practices supported by broader addiction-treatment research from interventions directly tested in ketamine or PCP disorder populations. Monitoring and a therapeutic relationship are clinically important even when no substance-specific medication has been validated.
The current state of ketamine treatment research
A 2024 systematic review of pharmacological treatment identified 12 studies involving 368 participants: one controlled trial, two retrospective case series, and nine case reports. Authors judged outcome quality very low, preventing confident estimates of benefit. A more extensive 2026 systematic review published online in July examined 73 studies, including five controlled clinical studies, 15 observational studies, 15 case series, and 38 case reports. It described heterogeneous supportive, psychological, and off-label medical interventions, with insufficient robust evidence to establish a standard treatment protocol. These reviews support clinical attention and further research, not claims that a medication or behavioral treatment is definitively effective specifically for ketamine use disorder.
Psychosocial care and motivational approaches
A collaborative clinical approach may include motivational interviewing, cognitive and behavioral formulations, relapse-prevention planning, practical support, and therapy addressing co-occurring disorders. Such approaches can help people identify triggers, establish goals, plan responses to craving, repair routines, and strengthen treatment engagement. General NICE psychosocial guidance for drug misuse supports motivational approaches and certain structured behavioral interventions in their relevant populations. The direct evidence that any one protocol reliably treats ketamine or PCP use disorder remains limited. Shared decision-making should communicate both the rationale for offering support and the uncertainty of substance-specific outcomes.
Cognitive behavioral techniques and recurrence prevention
Behavioral care can examine the chain connecting situations, expectations, emotions, craving, access, and use. Patients may practice identifying high-risk settings, creating alternatives to substance-centered activities, managing distress, and recruiting social support. Behavioral experiments and coping plans should fit the person's goals and capabilities. When bladder pain or cognitive symptoms interfere with treatment participation, coordinating medical care may be essential. The theoretical plausibility of these techniques does not establish efficacy for PCP dependence in the absence of appropriately controlled trials.
Contingency management and structured reinforcement
Contingency management uses planned reinforcement for measurable treatment goals, such as participation or verified reductions in substance use. It has an evidence base in certain other substance-use populations, especially stimulant-related care, and appears in NICE clinical recommendations. Evidence should not be transferred automatically across substances. Dedicated ketamine or PCP disorder trials are scarce, so any use of structured reinforcement should be represented as a clinically reasoned adaptation rather than an established disorder-specific intervention.
Is there an approved medication for ketamine or PCP addiction?
No medication has a well-established, specifically approved role as a definitive pharmacological treatment of ketamine or PCP use disorder. Reports describe off-label medications for craving, mood symptoms, agitation, or other clinical problems; findings are heterogeneous, often uncontrolled, and vulnerable to publication bias. The Roberts systematic review and Mosca systematic review do not justify declaring naltrexone, lamotrigine, benzodiazepines, antidepressants, or gabapentinoids proven treatments for ketamine addiction. Medication decisions belong to qualified clinicians and should address documented indications, interactions, and safety risks. Emergency sedation used to treat acute PCP toxicity is a separate intervention from maintenance treatment of a use disorder.
Treatment of urological and other medical complications
For patients with ketamine-related urinary symptoms, treatment of the use disorder should proceed in close coordination with urological assessment. Management can require addressing urinary pain, inflammation, infection when present, structural changes, kidney complications, and any obstruction. Continued ketamine exposure can undermine attempts to resolve symptoms, which makes substance-use care an integral part of the medical plan. The BAUS multidisciplinary consensus should guide specialist decisions; severe urinary findings require urgent clinical evaluation rather than self-directed symptom treatment.
When higher-intensity care may be appropriate
Outpatient care may meet the needs of a medically stable person who has sufficient support and can participate in treatment. More intensive addiction, psychiatric, or hospital services may be indicated for repeated dangerous intoxication, severe psychiatric symptoms, inability to maintain safety, co-occurring high-risk substance withdrawal, or significant urinary and renal complications. Level-of-care decisions should consider multiple dimensions rather than substance identity alone. The broader framework is addressed in Addiction Severity and Level of Care: How Treatment Needs Are Assessed.
Harm Reduction and Prevention of Acute Injury
Harm reduction aims to reduce disease, injury, and mortality while supporting access to care. For dissociative drugs, immediate priorities include recognizing impaired awareness and coordination, avoiding circumstances in which intoxication could lead to trauma or drowning, identifying dangerous co-exposures, and seeking emergency assistance for altered consciousness or severe physiological symptoms. Public-health and clinical care should provide accurate information and practical routes into assessment without requiring a person to declare one universal recovery goal before receiving help.
Co-use, uncertain products, and overdose risk
Combining dissociative drugs with alcohol, opioids, sedatives, or other psychoactive drugs complicates effects, increases the risk of injury and severe impairment, and may produce additional toxicity. A product sold as ketamine or PCP may contain something else. Emergency responders may need to address opioid overdose as a possibility when breathing is compromised, even if the reported exposure was a dissociative drug. Naloxone is appropriate when opioid poisoning is suspected according to emergency protocols; it does not specifically reverse NMDA-antagonist intoxication. A person with unresponsiveness, abnormal breathing, seizure, extreme agitation, or dangerous overheating requires emergency care.
Urinary symptoms as an early clinical opportunity
Pelvic pain, urgency, frequency, painful urination, or visible blood in urine can create an opportunity to identify ketamine-related problems before severe injury occurs. Patients should receive timely medical evaluation and an invitation to discuss exposure confidentially. Healthcare staff should consider the possibility of ketamine use while investigating alternative causes. The goal is early diagnosis of injury, improved continuity, and access to addiction and urological care. A normal initial investigation should not be interpreted as permanent protection from future complications if exposure continues.
Recovery, Remission, and Long-Term Functioning
Recovery refers to a broader process of improved control, health, safety, participation, relationships, and personally meaningful functioning. Diagnostic remission refers to a specified reduction or absence of symptoms under applicable criteria; it is narrower than overall recovery. Recurrence describes a return of problematic use or symptoms after improvement. A single episode of renewed use should prompt assessment of what changed and what support is needed, rather than a conclusion that previous gains have disappeared. Treatment goals should reflect the person's circumstances, medical findings, and preferences while continuing to address ongoing risk.
Craving and learned environmental cues
Craving may recur when a person encounters former settings of use, interpersonal stress, loneliness, emotional distress, or reminders of dissociative experiences. A recovery plan can map these cues and identify alternative actions, supportive contacts, access barriers, and ways to seek help promptly. Where bladder or other chronic pain persists, coordinated pain management and psychological care may be needed because untreated symptoms can affect sleep and coping. Progress is best evaluated through both substance-use outcomes and improvements in daily life.
Follow-up after stopping ketamine
Follow-up can address urinary and kidney function, cognition, mood, sleep, social participation, and co-occurring disorders. Improvement may occur at different rates across domains. Persistent hematuria, severe bladder pain, urinary obstruction, or significant renal concerns require ongoing specialist review regardless of abstinence status. A person who has stopped using ketamine may still need medical treatment, while someone who experiences renewed use benefits from early re-engagement with care. The urology consensus underlines the importance of longitudinal management for significant uropathy.
Social and structural conditions of recovery
Housing stability, access to affordable healthcare, supportive relationships, transportation, education, employment, and freedom from stigma can influence the feasibility of treatment. Social context also affects exposure and barriers to disclosure. Recovery support may include peer involvement, family collaboration when appropriate, and help navigating health systems. The specific effectiveness of individual peer or community interventions for ketamine or PCP disorder has not been defined by large high-quality trials, so the role of these resources is best understood within a person-centered, integrated plan.
Special Populations and Clinical Contexts
Adolescents and young adults may face developmental, social, educational, and consent-related concerns. Assessment should use developmentally appropriate language, involve caregivers according to safety and legal requirements, and examine school functioning, exploitation risks, and co-occurring mental health problems. Pregnancy introduces potential maternal and fetal concerns requiring specialized obstetric and addiction consultation rather than assumptions based on recreational or supervised medical exposure. Older adults and people with cardiovascular, renal, cognitive, or psychiatric vulnerability may experience additional risk from intoxication or medical complications.
Medical ketamine and esketamine treatment
A person receiving prescribed ketamine or esketamine should be assessed according to the actual indication, treatment setting, monitoring, and behavior around the medication. Controlled clinical administration differs from repeated nonmedical consumption in exposure, supervision, population, and observed outcomes. Therapeutic benefit in depression cannot be inferred from uncontrolled recreational use, and ketamine use disorder cannot be treated simply by adopting protocols studied for depression. The distinct medical-treatment evidence is considered in Ketamine and Esketamine for Depression: Evidence and Safety.
Ketamine studied as a treatment for other addictions
Research has also tested administered ketamine as an experimental intervention for some other substance use disorders. A 2025 systematic review examined heterogeneous studies across alcohol, cocaine, opioid, and cannabis conditions, reporting preliminary findings and substantial research limitations. Those experiments do not demonstrate that ketamine treats its own problematic use and do not justify self-administration. Clinical treatment studies require regulated settings, medical screening, protocols, and evaluation of misuse potential. This distinction prevents an apparent contradiction between ketamine as a medication under investigation and ketamine as a substance associated with addiction and physical harm.
What the Evidence Can and Cannot Establish
The strongest specific clinical foundation here concerns recognized acute toxic syndromes, the diagnostic distinction between intoxication and a use disorder, and the clinically observed pattern of ketamine-associated urinary tract injury. Evidence about optimal ketamine-dependence treatment is far less conclusive. The methodological gap is an important finding, because clinicians and patients may encounter confident treatment claims based on small series or isolated successes.
Established evidence
Ketamine and PCP are dissociative NMDA receptor antagonists with potentially serious acute effects; PCP can cause medically dangerous intoxication, and frequent ketamine use is associated with clinically significant urinary tract injury. Dependence and substance use disorders due to dissociative drugs are recognized within international classification. Recognizing emergency warning signs, providing acute medical care, and investigating urinary symptoms are established clinical priorities. These conclusions are supported by WHO diagnostic guidance, PCP toxicology guidance, and urological consensus statements.
Preliminary or limited findings
Psychosocial interventions used in broader addiction care have reasonable clinical rationales, but ketamine- and PCP-specific comparative evidence is sparse. Candidate medications for ketamine craving or dependence have mostly been evaluated in case reports, case series, and other heterogeneous studies; convincing efficacy estimates remain unavailable. Neuroimaging associations and many reports of cognitive changes are observational and vulnerable to confounding. Evidence for long-term outcomes after cessation of ketamine use is incomplete, especially across populations with different exposure histories. The 2024 and 2026 systematic reviews document these gaps.
Important contested or unresolved questions
Key unresolved issues include how to define and measure a reproducible ketamine withdrawal syndrome; which interventions produce durable improvements in control and functioning; how much observed neurocognitive change is attributable directly to exposure; why severe uropathy develops in some individuals and not others; and which clinical markers predict recovery of bladder function. Different diagnostic classifications and inconsistent study criteria complicate pooling and comparison. More prospective cohorts and adequately controlled studies with standardized outcomes are needed. Causal conclusions should reflect study design, not the number of times a proposed mechanism appears in secondary reports.
Frequently Asked Questions
Can a person become addicted to ketamine?
Yes. Repeated nonmedical ketamine use can become difficult to control and meet the clinical requirements of a substance use disorder. The diagnosis depends on craving, impaired control, continued use despite harm, and related functional consequences, rather than merely having tried ketamine. People may experience important physical injury with or without a formal use-disorder diagnosis. Assessment should also evaluate psychiatric conditions and other substance exposure.
Is PCP addiction the same condition as ketamine addiction?
They are closely related within dissociative-drug classification, but their typical exposure histories, acute risks, and evidence bases differ. PCP has a particularly prominent severe acute toxicology profile, while sustained nonmedical ketamine use has an especially well-described urinary complication pattern. Clinicians must apply the diagnostic framework to each person's actual symptoms and exposure history rather than assume identical trajectories.
Is ketamine withdrawal life-threatening?
A uniform physiological ketamine withdrawal syndrome has not been established in the manner recognized for alcohol or benzodiazepines. Stopping frequent use may nevertheless bring significant craving, mood symptoms, sleep changes, or other distress. People who also use alcohol, benzodiazepines, or other drugs can face separate dangerous withdrawal or medical risks. New seizures, severe confusion, psychosis, suicidal intent, or other emergency symptoms always warrant prompt medical attention.
Does ketamine permanently damage the bladder?
Ketamine-associated urinary injury can be serious, and in advanced cases some damage or functional limitation may persist. Symptoms may improve after exposure stops, especially when problems are identified and treated early, but recovery is variable. Persistent urinary pain, blood in urine, retention, infection symptoms, or kidney concerns need medical investigation and sometimes specialist follow-up. Urology consensus guidance offers a structured clinical approach.
Can ketamine use disorder be diagnosed with a urine test?
No. Urine testing may sometimes provide evidence of substance exposure, but a use disorder is diagnosed through a clinical assessment of symptoms, control, duration, consequences, and impairment. Standard panels do not universally include ketamine, and PCP immunoassays may be misleading. Testing results are interpreted alongside history and examination, particularly in emergencies.
Is ketamine approved to treat ketamine addiction?
No established clinical standard supports prescribing ketamine itself as treatment for ketamine use disorder. Research into medically supervised ketamine for other substance use disorders has distinct goals, populations, and risks and remains preliminary. Similarly, no medication has demonstrated a sufficiently robust, disorder-specific evidence base to serve as a definitive approved treatment for PCP or ketamine addiction. Integrated medical and psychological care remains central.
When should someone seek emergency help after ketamine or PCP use?
Call emergency services for unconsciousness or difficulty awakening, abnormal breathing, seizure, high body temperature, severe agitation or confusion, chest pain, serious injury, or immediate risk of self-harm. Severe urinary bleeding, inability to urinate, fever with urinary symptoms, or intense flank pain also warrants urgent evaluation. Do not assume that an unusual mental state is harmless simply because dissociative drugs are involved.
Clinical Synthesis
Dissociative drug use disorders combine changes in the regulation of substance use with substance-specific medical and psychiatric risks. Ketamine and PCP share a dissociative pharmacological foundation, yet ketamine-associated urinary injury and the potentially severe acute toxicity of PCP demand different emphases in assessment. Diagnosis rests on clinical criteria and a longitudinal understanding of behavior, function, and consequences. Emergency stabilization, treatment of physical complications, coordinated psychiatric care, psychosocial support, and continuing recovery planning each address a different part of the problem. Contemporary systematic reviews establish the limits of ketamine-specific treatment evidence, supporting individualized care and careful communication about what interventions have actually been tested.
Related Articles
Cluster Substance Use Disorders and Addiction Recovery — the published scientific overview of clinical substance use disorders, treatment, and recovery.
Substance Use Disorder: Symptoms, Diagnosis, and Treatment — shared clinical definitions and diagnostic assessment.
Substance Intoxication vs Withdrawal: Symptoms and Clinical Assessment — acute syndrome assessment and safety.
Substance-Induced Psychosis: Causes, Symptoms, and Treatment — differential diagnosis of substance-related psychosis.
Addiction Severity and Level of Care: How Treatment Needs Are Assessed — selection and reassessment of appropriate care intensity.
Ketamine and Esketamine for Depression: Evidence and Safety — the separate clinical use and safety evidence.
Ketamine for OCD: What Does the Evidence Show? Rapid Effects, Research Status, Risks, and Limitations — research on a distinct therapeutic application.
Dissociative Disorders: Types, Symptoms, Diagnosis, and Treatment — primary dissociative mental disorders and differential diagnosis.
Inhalant Use Disorder: Symptoms, Risks, and Treatment — a neighboring substance-specific diagnostic article about toxic exposures and clinical care.
References
Belal, M., Downey, A., Doherty, R., Ali, A., Hashim, H., Kozan, A., Kujawa, M., Pakzad, M., Rashid, T., Osman, N., Sahai, A., Biers, S., and the BAUS Section of Female, Neurological and Urodynamic Urology. (2024). British Association of Urological Surgeons consensus statements on the management of ketamine uropathy. BJU International, 134(2), 148–154. https://doi.org/10.1111/bju.16404
Janssen-Aguilar, R., et al. (2025). Role of ketamine in the treatment of substance use disorders: A systematic review. Journal of Substance Use and Addiction Treatment, 175, 209705. https://doi.org/10.1016/j.josat.2025.209705
Mosca, A., Chiappini, S., Miuli, A., Corkery, J. M., Piro, T., Allegretti, R., Ciraselli, N., Marrangone, C., Schifano, N., Pettorruso, M., Martinotti, G., and Schifano, F. (2026; published online July 1). Treatment and management approaches for ketamine misuse: A systematic review of medical interventions. Journal of Substance Use and Addiction Treatment, 191, 210061. https://doi.org/10.1016/j.josat.2026.210061
National Center for Biotechnology Information. (2023). Phencyclidine toxicity. StatPearls, NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK507865/
National Institute for Health and Care Excellence. (2007). Drug misuse in over 16s: Psychosocial interventions (Clinical guideline CG51). https://www.nice.org.uk/guidance/cg51/chapter/recommendations
Roberts, E., Sanderson, E., and Guerrini, I. (2024). The pharmacological management of ketamine use disorder: A systematic review. Journal of Addiction Medicine, 18(5), 574–579. https://doi.org/10.1097/ADM.0000000000001340
Substance Abuse and Mental Health Services Administration. (n.d.). Co-occurring mental health and substance use disorders. https://www.samhsa.gov/mental-health/serious-mental-illness/co-occurring-disorders
Strous, J. F. M., Weeland, C. J., van der Draai, F. A., Daams, J. G., Denys, D., Lok, A., Schoevers, R. A., and Figee, M. (2022). Brain changes associated with long-term ketamine abuse, a systematic review. Frontiers in Neuroanatomy, 16, 795231. https://doi.org/10.3389/fnana.2022.795231
World Health Organization. (2024). Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders. https://www.who.int/publications/i/item/9789240077263